Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019;173(1):37–48.

Article  PubMed  Google Scholar 

Palmieri C, Owide J, Fryer K. Estimated prevalence of metastatic breast cancer in England, 2016–2021. JAMA Netw Open. 2022;5(12): e2248069.

Article  PubMed  PubMed Central  Google Scholar 

Sedeta ET, Jobre B, Avezbakiyev B. Breast cancer: global patterns of incidence, mortality, and trends. J Clin Oncol. 2023;41(16_suppl):10528.

Article  Google Scholar 

Lim YX, Lim ZL, Ho PJ, Li J. Breast cancer in asia: incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. Cancers (Basel). 2022;14(17):4218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rajappa S, Singh M, Uehara R, Schachterle SE, Setia S. Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020. Curr Med Res Opin. 2023;39(8):1127–37.

Article  PubMed  Google Scholar 

O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30.

Article  CAS  PubMed  Google Scholar 

Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317–31.

Article  CAS  PubMed  Google Scholar 

Battisti NML, Ring A. CDK4/6 inhibition in HER2-positive breast cancer. Lancet Oncol. 2020;21(6):734–5.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Breast Cancer 2024 [updated 3 July 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open. 2023;8(3): 101541.

Article  PubMed  PubMed Central  Google Scholar 

Kish JK, Ward MA, Garofalo D, Ahmed HV, McRoy L, Laney J, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res BCR. 2018;20(1):37.

Article  CAS  PubMed  Google Scholar 

Beachler DC, de Luise C, Jamal-Allial A, Yin R, Taylor DH, Suzuki A, et al. Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. BMC Cancer. 2021;21(1):97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res BCR. 2021;23(1):37.

Article  CAS  PubMed  Google Scholar 

Cardoso Borges F, Alves da Costa F, Ramos A, Ramos C, Bernardo C, Brito C, et al. Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: results from a population-based cohort study. Breast. 2022;62:135–43.

Article  PubMed  PubMed Central  Google Scholar 

Kraus AL, Yu-Kite M, Mardekian J, Cotter MJ, Kim S, Decembrino J, et al. Real-world data of palbociclib in combination with endocrine therapy for the treatment of metastatic breast cancer in men. Clin Pharmacol Ther. 2022;111(1):302–9.

Article  CAS  PubMed  Google Scholar 

Mycock K, Zhan L, Hart K, Taylor-Stokes G, Milligan G, Atkinson C, et al. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study. Future Oncol (London, England). 2022;18(3):349–62.

Article  CAS  Google Scholar 

Mycock K, Hanson KA, Taylor-Stokes G, Milligan G, Atkinson C, Mitra D, et al. Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the ibrance real world insights study. Clin Ther. 2022;44(12):1588–601.

Article  CAS  PubMed  Google Scholar 

Tripathy D, Rocque G, Blum JL, Karuturi MS, McCune S, Kurian S, et al. 251P Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor–positive advanced breast cancer: results from the POLARIS trial. Ann Oncol. 2022;33:S651–2.

Article  Google Scholar 

DeMichele A, Robert N, Chen C, Kim S, Zhang Z, Lu DR, et al. Real-world tumor response of palbociclib in combination with an aromatase inhibitor as first-line therapy in pre/perimenopausal women with metastatic breast cancer. Target Oncol. 2023;18(4):543–58.

Article  PubMed  PubMed Central  Google Scholar 

Lok SW, Tung I, Anton A, Baron-Hay SE, De Boer RH, Boyle FM, et al. Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry. J Clin Oncol. 2023;41(16):e13054.

Article  Google Scholar 

Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, Macpherson IR, et al. A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. Br J Cancer. 2023;129:159–60.

Article  Google Scholar 

US Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry 2020. https://www.fda.gov/media/127712/download.

Brufsky A, Gallagher C. P-REALITY X: a real-world analysis of palbociclib plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer-a podcast. Target Oncol. 2023;18(3):321–6.

Article  PubMed  PubMed Central  Google Scholar 

Ranganathan K, Singh P, Wilkins EG, Hamill JB, Aliu O, Newman L, et al. Abstract 03: the global macroeconomic burden of breast cancer: implications for oncologic and reconstructive surgery. Plast Reconstr Surg Glob Open. 2018;6(4 Suppl):2–3.

Article  PubMed Central  Google Scholar 

Ji P, Gong Y, Jin ML, Hu X, Di GH, Shao ZM. The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017. Front Oncol. 2020;10:650.

Article  PubMed  PubMed Central  Google Scholar 

Shau WY, Setia S, Shinde S, Santoso H, Furtner D. Generating fit-for-purpose real-world evidence in Asia: how far are we from closing the gaps? Perspect Clin Res. 2023;14(3):108–13.

Article  PubMed  PubMed Central  Google Scholar 

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.

Article  PubMed  Google Scholar 

Ogden K, Thompson JC, Halfpenny NJ, Scott DA. A conceptual search filter to identify real-world evidence. Value in Health. 2015;18(7):A728.

Article  Google Scholar 

Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2022;52(5):616–27.

Article  CAS  Google Scholar 

Deitelzweig S, Bergrath E, di Fusco M, Kang A, Savone M, Cappelleri JC, et al. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. Future Cardiol. 2022;18(5):393–405.

Article  CAS  PubMed  Google Scholar 

Shau WY, Setia S, Shinde SP, Santoso H, Furtner D. Contemporary databases in real-world studies regarding the diverse health care systems of India, Thailand, and Taiwan: protocol for a scoping review. JMIR Res Protoc. 2022;11(12): e43741.

Article  PubMed  PubMed Central  Google Scholar 

Adis International Ltd. Palbociclib—Chia Tai Tianqing Pharmaceutical 2023 [updated 05 May 2023]. https://adisinsight.springer.com/drugs/800051802.

Adis International Ltd. Palbociclib—onyx pharmaceuticals/Pfizer 2023 [updated 02 Jul 2023]. https://adisinsight.springer.com/drugs/800020668.

Shvili J. The Western Wo